Our previous analysis confirmed that treatment of non-diabetic patients with HER2+ BC with oral metformin (850 mg twice daily) for 24 weeks produced blood levels of circulating metformin of ~7 μmol/L, equivalent to those generally achieved in diabetic patients with the usual clinical doses and schedule [17]. This evidence concerns the gene ERBB2 and breast cancer.